SMART 2D: Study of Montelukast's Effects on Renal and Cardiovascular Health in Adolescents and Young Adults With Type 2 Diabetes
Eligible age
14–24 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Adolescents and young adults (AYA) with type 2 diabetes (T2D) have a more severe phenotype than what is seen in youth-onset type 1 diabetes or adult-onset T2D including earlier kidney and cardiovascular disease complications; and prioritizing new treatments, either for standalone use or in combination with other therapies is critical. T2D triggers the release of proinflammatory mediators called cysteinyl leukotrienes leading to damage to the kidneys and blood vessels. This clinical trial will evaluate the effects of montelukast, a cysteinyl leukotriene inhibitor, on kidney and vascular function in AYA with T2D to help direct future diabetes care to limit diabetic kidney and cardiovascular disease complications.
Sponsor: University of Colorado, Denver
You may qualify if…
- ✓ Age 14-24 years
- ✓ Tanner stage \>2
- ✓ Diabetes onset \<18 years of age and \<10 years duration prior to study start
- ✓ HgbA1c \<10%
- ✓ Blood pressure \<130/80 mm Hg prior to randomization
- ✓ Stable anti-hypertensive regimen for at least one month prior to randomization
- ✓ BMI \< 40 kg/m2
- ✓ If on SGLT2 inhibitor, ACEi/ARB or GLP-1RA, stable dose for 4 weeks
You may not qualify if…
- ✕ T1D
- ✕ Episode of diabetic ketoacidosis or hyperosmolar hyperglycemia within 60 days
- ✕ Uncontrolled hypertension
- ✕ eGFR \<30 ml/min/1.73m2
- ✕ Macroalbuminuria with urine albumin to creatinine ratio \>300 mg/g
- ✕ Current participation in another research study
- ✕ Pregnancy or planning to become pregnant or currently breastfeeding
- ✕ Allergy to aspirin
Where it's recruiting
Aurora
Source: ClinicalTrials.gov · NCT07409714 · last updated 2026-09-09